180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to shareholders; the letter is signed by CEO James Woody. In the letter, Woody notes that the company’s priority continues to be its clinical programs, repurposing anti-tumor necrosis factor (“TNF”) drugs for the treatment of Dupuytren’s disease, frozen shoulder and post-operative delirium. Woody reports that results from the company’s phase 2B trial exceeded expectations and showed that the treatment will most likely be cost effective. In the letter, Woody stated that, after obtaining scientific advice from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) and after discussions with regulatory consultants in the United States and United Kingdom, the company is preparing the material required to seek marketing authorization in the UK; the company plans on filing the application in mid-2023. “Enrollment to the trial of anti-TNF for early-stage frozen shoulder is slower than anticipated in the UK as patients typically present to physical therapists and the processes are subject to delays,” stated 180 Life Sciences CEO James Woody in the shareholder letter. “In the USA, all such patients are seen by orthopedic physicians, who are relatively easy to access. The trial team has implemented several strategies to improve recruitment, and we hope that these will be effective. Preparation for the trial of anti-TNF to prevent the development of postoperative delirium remains on track, and we anticipate that the first patient will be recruited in the first half of 2023. Our focus remains on our clinical portfolio. . . and we plan to continue to evaluate the timing and cost/benefit of additional ongoing research for our early discovery programs.”
To view the full shareholder letter, visit https://ibn.fm/ZkCj1
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease: inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
